Horizon Therapeutics Plc

HZNP NASDAQ
25.57
-0.38
-1.46%
After Hours: 25.45 -0.12 -0.47% 17:14 05/22 EDT
Open
25.89
Prev Close
25.95
High
26.12
Low
25.11
Volume
1.31M
Avg Vol (3M)
1.96M
52 Week High
29.44
52 Week Low
14.89
% Turnover
0.71%
Market Cap
4.73B
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Company Profile

Horizon Therapeutics PLC, formerly Horizon Pharma Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).
MORE >

Recently

Name
Price
%Change